Therapie最新文献

{"title":"[ISO 9001 certification: Experience of the immunology and cell therapy laboratory at Ibn Sina University Hospital, Rabat].","authors":"Nada Saout, Ouafa Atouf, Malika Essakalli","doi":"10.1016/j.therap.2024.11.005","DOIUrl":"https://doi.org/10.1016/j.therap.2024.11.005","url":null,"abstract":"<p><p>Medical analysis laboratories play an essential role in medical diagnosis, with their results influencing up to 70% of decisions. This means that the quality of laboratory services is a key factor in the quality of medical care. However, certification and accreditation are not yet compulsory in Morocco, and only the Guide to the Good Execution of Medical Biology Analyses (GBEA) published in 2011 governs the organisation of laboratories. The Blood Transfusion and Hemovigilance Service (STSH) at the Ibn Sina University Hospital (CHUIS) in Rabat has embarked on an ISO 9001:2015 certification process, with the aim of improving its performance and satisfying its interested parties. This process, which was launched in 2018, was carried out in two main phases. The first phase consisted of complying with current regulations, while the second phase involved an evaluation based on the ISO 9001:2015 standard. In accordance with the logic of the Deming wheel, the department developed its quality policy, set its objectives, and undertook staff training and awareness activities. The processes, along with the associated risks and opportunities, have been identified and represented. The documentation system, as well as the system for reporting and handling non-conformities, has been implemented and dematerialised. Performance and activity indicators have been defined for each process. Finally, the customer feedback system has been expanded to include all interested parties, thus allowing for an evaluation of their perceptions and the identification of areas for improvement. Despite the global pandemic of COVID-19, this work has successfully integrated ISO 9001:2015 into STSH's practices, with compliance being declared by a certification body in 2022.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The French Addictovigilance Network - A multidisciplinary successful journey in the protection of public health.","authors":"Ana Carmona Araújo","doi":"10.1016/j.therap.2024.11.009","DOIUrl":"https://doi.org/10.1016/j.therap.2024.11.009","url":null,"abstract":"<p><p>Since the beginning of the century, the USA have been experiencing an opioid epidemic characterised by high levels of prescription opioid use. While extensive North American literature on the topic has been published and several public health measures implemented attempting to address the problem, in Europe addiction research, especially literature focusing on misuse of medicines, lags far behind. France is an exception: it is the only European country that has established a nationwide specific system to monitor misuse of legal and illegal psychoactive substances, an activity that has been named addictovigilance. Thanks to the combined use of several data sources, the French addictovigilance system has, in its three decades of existence, proven to be effective in the early identification and assessment of addictovigilance signals, providing real-world evidence to support the conception and monitoring of public health measures to minimise the health risks posed by psychoactive substance misuse in France.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring opioid analgesic misuse, abuse and dependence: What to the data from addictovigilance tell us about the situation in France?","authors":"Maryse Lapeyre-Mestre, Celian Bertin, Constança Jalles, Thomas Soeiro, Joëlle Micallef, Anne Roussin","doi":"10.1016/j.therap.2024.11.008","DOIUrl":"https://doi.org/10.1016/j.therap.2024.11.008","url":null,"abstract":"<p><p>The opioid epidemic has emerged in the USA in the late 1990s and widespread to Canada, Australia, and the UK to a lesser extent in the more recent years. At the European level, several studies performed in different European countries have highlighted that prescription opioid use increased substantially over the last decade, and several proxies for misuse show a parallel increasing trend. The French addictovigilance experience on opioid analgesics is a good example of a specific dedicated monitoring, taking into account in a global and multisource perspective, patterns of utilization, population involved in problematic use, ways of acquisition and health complications. The added value of this data triangulation is illustrated by the recent data on tramadol and oxycodone. The addictovigilance monitoring is particularly relevant to identify early signals of potential problematic use and to assess the impact of campaigns for opioid analgesics rational use and regulatory changes.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Acute cytolytic hepatitis followed by edema associated with the use of antipsychotics neuroleptics: A case report and review of the literature].","authors":"Fatma Guermazi, Rabeb Jbir, Imen Bouaziz, Rim Atheymen, Dorra Mnif, Nourelhouda Ben Ali, Kamilia Ksouda, Khaled Zghal, Imen Baati, Jawaher Masmoudi","doi":"10.1016/j.therap.2024.11.004","DOIUrl":"https://doi.org/10.1016/j.therap.2024.11.004","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxybutynin induced blindness in a child: Case report.","authors":"Mouna Daldoul, Ahmed Zaiem, Yasmine Salem Mahjoubi, Ons Charfi, Ghozlane Lakhoua, Sarrah Kastalli, Riadh Daghfous, Imen Aouinti, Sihem El Aidli","doi":"10.1016/j.therap.2024.11.003","DOIUrl":"https://doi.org/10.1016/j.therap.2024.11.003","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The enhanced national pharmacovigilance system implemented for COVID-19 vaccines in France: A 2-year experience report.","authors":"Samuel Crommelynck, Aurélie Grandvuillemin, Claire Ferard, Céline Mounier, Nathalie Gault, Evelyne Pierron, Baptiste Jacquot, Tiphaine Vaillant, Isabelle Parent du Chatelet, Alexis Jacquet, Francesco Salvo, Martine Alt, Haleh Bagheri, Joëlle Micallef, Antoine Pariente, Sophie Gautier, Marie-Blanche Valnet-Rabier, Marina Atzenhoffer, Marion Lepelley, Judith Cottin, Isabelle Lacroix, Valérie Gras, Nathalie Massy, Alban Dhanani, Philippe Vella, Youssef Shaim, Laurence Baril, Annie-Pierre Jonville-Béra, Mehdi Benkebil","doi":"10.1016/j.therap.2024.11.002","DOIUrl":"https://doi.org/10.1016/j.therap.2024.11.002","url":null,"abstract":"<p><p>In March 2020, World Health Organization recognized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emergence as a public health emergency of international concern. One of the major preventative measures developed against coronavirus disease 2019 (COVID-19) was vaccines. To monitor their use and safety of vaccines from the first utilization in humans during clinical development phases to implementation for the general population, an enhanced national pharmacovigilance system was enabled by the French National Agency for Medicines and Health Products Safety in collaboration with the 30 Regional Pharmacovigilance Centres. Here, we review the significant outcomes from a 2-year collaboration experience between the French National Agency for Medicines and Health Products Safety, the 30 Regional Pharmacovigilance Centres, disease-related experts and the pharmacovigilance and risk assessment committee at the European medicine agency. In France, until January 2023, over 155 million doses of COVID-19 vaccines were administrated, and 190,000 adverse events following immunizations (25% classified as serious) were analysed. Altogether 53 potential safety signals were reported to the Pharmacovigilance and Risk Assessment Committee at the European Medicine Agency by the French National Agency for Medicines and Health Products Safety: 13 were confirmed, 24 are still under investigation and 16 were not confirmed. The enhanced national PV system contributed actively better to define the safety profile of the newly developed vaccines, and the French National Agency for Medicines and Health Products Safety continues to monitor the benefit and risks of the COVID-19 vaccines.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142786791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physicians, pharmacists and take-home naloxone: What practices? The SINFONI study","authors":"Mélanie Duval ,&nbsp;Aurélie Aquizerate ,&nbsp;Emmanuelle Jaulin ,&nbsp;Morgane Rousselet ,&nbsp;Emmanuelle Kuhn ,&nbsp;Alain Guilleminot ,&nbsp;Isabelle Nicolleau ,&nbsp;Solen Pele ,&nbsp;Thomas Herault ,&nbsp;Pascal Artarit ,&nbsp;Eleni Soulidou-Jacques ,&nbsp;Edouard-Jules Laforgue ,&nbsp;Caroline Victorri-Vigneau","doi":"10.1016/j.therap.2024.07.001","DOIUrl":"10.1016/j.therap.2024.07.001","url":null,"abstract":"<div><h3>Objective</h3><div>For several years, both the French Addictovigilance Network and French health authorities have consistently emphasized the need to provide opioid users with take-home naloxone (THN), the specific antidote for opioid overdoses. In March 2022, the French Health Authority recommended systematically assessing the appropriateness of prescribing THN to all opioid users, regardless of the context, and identified 8 high-risk situations. However, at present, THN distribution remains limited, particularly among primary care healthcare professionals. This study, conducted by the Pays de la Loire Centre for Evaluation and Information on Drug Dependence-Addictovigilance and supported by the Regional Health Agency, aims to explore healthcare professionals’ practices and perceptions of these high-risk situations.</div></div><div><h3>Methods</h3><div>An ad-hoc questionnaire was distributed via mail by the project's regional institutional partners to the target healthcare professionals: pharmacists, general practitioners (GPs), physicians practicing in specialities other than general medicine (SPs: algologists, psychiatrists and addictologists). It was completed online from 20/10/2022 to 30/12/2022.</div></div><div><h3>Results</h3><div>Out of the 355 participants (158 pharmacists, 167 GPs and 30 SPs), nearly all were managing patients on opioids. In total, 47.7% of physicians and 27.8% of pharmacists reported experiencing difficulties in dealing with the risk of overdose when prescribing or dispensing opioids to their patients. In the 12<!--> <!-->months preceding the study, only 8 pharmacists and 34 physicians had prescribed/dispensed THN, primarily due to a lack of awareness of its existence (52% of pharmacists and 72% of physicians) and challenges in addressing the eight overdose risk situations listed by the HAS (ranging from 54% to 83% for all professionals). The best-trained healthcare professionals were those who prescribed the most THN (<em>P</em> <!-->&lt;<!--> <!-->0.001).</div></div><div><h3>Conclusion</h3><div>The identification of barriers related to THN distribution in the regional SINFONI study, conducted among primary care healthcare professionals managing patients on opioids, highlights the need to develop a training tool specifically tailored for these professionals.</div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"79 6","pages":"Pages 623-633"},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141715325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exposure assessment of titanium dioxide via drugs available on the French market: A nationwide descriptive study","authors":"Manon Cairat ,&nbsp;Inge Huybrechts ,&nbsp;Agnès Fournier","doi":"10.1016/j.therap.2024.07.005","DOIUrl":"10.1016/j.therap.2024.07.005","url":null,"abstract":"<div><h3>Purpose</h3><div>Based on potential adverse health effects including genotoxicity concerns, the European Union banned titanium dioxide (TiO₂) as a food additive in 2022, but food-grade TiO₂ can still be used in pharmaceutical products.</div></div><div><h3>Methods</h3><div>This study described the presence of TiO₂ in drugs available on the French market and estimated the population exposure to TiO₂ through drug consumption. We used annual drug claim data aggregated at the national level together with data on the TiO₂ content of pharmaceutical products available on the French market in 2001–2020.</div></div><div><h3>Results</h3><div>Of the 17 171 pharmaceutical specialties identified on the French market between 2001 and 2020, 38% contained TiO₂. That figure reached 95% for capsules, 92% for film-coated tablets, 74% for coated tablets and 66% for soft capsules. Only 1% of non-oral specialties contained TiO₂. The median TiO₂ amount in one common dispensing unit was 1.5<!--> <!-->mg for oral specialties containing TiO₂. We estimated that the mean exposure to TiO₂ per inhabitant through the consumption of reimbursed drugs between 2012 and 2020 was 1.71<!--> <!-->mg per day, with women (1.81<!--> <!-->mg/d) slightly more exposed than men (1.54<!--> <!-->mg/d) and people older than 59 years (4.00<!--> <!-->mg/d) much more exposed than younger people (1.24 and 0.21<!--> <!-->mg/d for 20–59 and<!--> <!-->&lt;<!--> <!-->20 years old individuals, respectively).</div></div><div><h3>Conclusion</h3><div>This study highlights a widespread presence of TiO₂ in drugs on the French market. The health impact of exposure to TiO₂ through drug consumption should be evaluated in future epidemiological studies.</div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"79 6","pages":"Pages 718-729"},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Judiciarisation des produits à base de cannabidiol au Brésil : une analyse de 2019 à 2022","authors":"Ronaldo Portela Portela ,&nbsp;Mariana Dias Lula ,&nbsp;Maria Laura Silva ,&nbsp;Cristina Mariano Ruas","doi":"10.1016/j.therap.2024.10.023","DOIUrl":"10.1016/j.therap.2024.10.023","url":null,"abstract":"<div><h3>Introduction</h3><div>L’étude a analysé les poursuites judiciaires des patients qui ont sollicité l’accès à des produits à base de cannabidiol (CBD) au système national santé (universel) brésilien durant la période de 2019 à 2022, en décrivant les caractéristiques sociodémographiques, cliniques et juridiques.</div></div><div><h3>Matériels et méthode</h3><div>Il s’agit d’une étude transversale composée de l’évaluation des notes techniques émises par le Centre d’appui technique du pouvoir judiciaire (NatJus), qui soutiennent les décisions judiciaires. Les données ont été obtenues à partir du système e-NatJus, du ministère la Justice au Brésil, en utilisant des techniques de Web scraping. Une régression logistique a été utilisée pour estimer les <em>odds ratio</em> (IC 95 %).</div></div><div><h3>Résultats</h3><div>Nous avons analysé 1115 notes techniques des plaignants CBD, soit 54,7 % des patients de sexe masculin, d’âge moyen 18,4 ans, provenant de la région sud du pays (38,8 %), dont 49,6 % dans le cadre du traitement pour l’épilepsie. En ce qui concerne les actes avec avis favorable : 28,8 % n’avaient aucune preuve scientifique ; 26,5 % plaidaient pour des produits sans enregistrement auprès de l’Agence nationale de sécurité des médicaments et produits de santé du Brésil (ANVISA) ; 25,3 % plaident pour des produits enregistres à l’ANVISA mais n’était pas conformes à l’indication thérapeutique sollicitée.</div></div><div><h3>Conclusion</h3><div>Les patients de la région nord-est avaient une chance augmentée de 3,0 fois d’obtenir un avis favorable et ceux diagnostiqués avec une épilepsie de 2,3 fois. Les avis d’experts qui ont soutenu les magistrats pour les décisions judiciaires concernant les demandes des patients pour des produits à base de cannabidiol au Brésil étaient pour la plupart conformes aux preuves scientifiques, dénotant l’importance de NatJus dans la qualification de l’accès aux médicaments dans le pays.</div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"79 6","pages":"Page 749"},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142699022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Évaluation de la consommation de substances psychoactives avant incarcération : données de l’enquête OPPIDUM","authors":"Zeinab Abbas ,&nbsp;Sabrine Mouas ,&nbsp;Clémence Lacroix ,&nbsp;Elisabeth Jouve ,&nbsp;Céline Eiden ,&nbsp;Hélène Peyrière ,&nbsp;Réseau français des centres d’addictovigilance","doi":"10.1016/j.therap.2024.10.036","DOIUrl":"10.1016/j.therap.2024.10.036","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Les troubles de l’usage (TLU) de substances psychoactives (SPA) sont des enjeux majeurs de santé publique, et les sujets incarcérés sont particulièrement exposés à ces risques &lt;span&gt;&lt;span&gt;[1]&lt;/span&gt;&lt;/span&gt;. La connaissance des habitudes de consommation avant l’incarcération permet un meilleur accompagnement des patients &lt;span&gt;&lt;span&gt;[1]&lt;/span&gt;&lt;/span&gt;. Notre objectif était d’analyser les données de l’enquête OPPIDUM (Observation des produits psychotropes illicites ou détournés de leur utilisation médicamenteuse), réalisée auprès de sujets incarcérés.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Matériel et méthodes&lt;/h3&gt;&lt;div&gt;Les données ont été extraites de l’enquête annuelle, multicentrique et transversale, OPPIDUM &lt;span&gt;&lt;span&gt;[2]&lt;/span&gt;&lt;/span&gt;, réalisée auprès d’usagers de SPA vus dans des centres spécialisés, sur la période 2013–2022. Les sujets incarcérés ont été questionnés sur leur usage de SPA la semaine précédant leur incarcération. Deux groupes de sujets ont été comparés : ceux ayant déclaré un usage simple de SPA et ceux avec TLU.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Résultats&lt;/h3&gt;&lt;div&gt;Au total, 2626 individus ont répondu à l’enquête, représentant 5352 substances. La comparaison des données usage simple/TLU a été réalisée chez 1142 participants (hommes 91,3 %) pour lesquels l’information était disponible, correspondant à 3674 produits, avec un âge moyen de 33,6&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;8,9 ans. Les substances significativement (&lt;em&gt;p&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0,001) plus fréquemment consommées dans le groupe TLU/usage simple sont le cannabis (30 %/6,5 %), la cocaïne/crack (16,3 %/3,3 %), les benzodiazépines (10,1 %/5,4 %) et l’héroïne (9,2 %/0,8 %) : sur la période, une stabilité des SPA impliquées dans les TLU est observée. Un traitement de substitution aux opioïdes (TSO) était présent dans 51,1 % des sujets pour la méthadone et 48,7 % pour la buprénorphine.&lt;/div&gt;&lt;div&gt;Plusieurs variables sont associées à un risque significativement augmenté de TLU : la consommation de tabac (OR : 2979 ; IC&lt;sub&gt;95 %&lt;/sub&gt; : 1,5–5,8, &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0,001), d’alcool (OR : 2,08 ; IC&lt;sub&gt;95 %&lt;/sub&gt; : 1,5–2,7, &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0,001), de SPA injectables (OR : 2805, IC&lt;sub&gt;95 %&lt;/sub&gt; :1,6–4,9, &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0,0001), l’acquisition illégale des SPA (OR : 13,8, IC&lt;sub&gt;95 %&lt;/sub&gt; : 8,9–21,3, &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0,0001) et une consommation quotidienne ou hebdomadaire par rapport à une consommation mensuelle (OR : 6,730, IC&lt;sub&gt;95 %&lt;/sub&gt; : 4,7–9,7, &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0,0001 et OR : 4,789, IC&lt;sub&gt;95 %&lt;/sub&gt; : 3,2–6,9, &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0,0001). À l’inverse, des variables ont été associées à un risque plus faible de TLU : suivre un protocole TSO (OR : 0,617, IC&lt;sub&gt;95 %&lt;/sub&gt; : 0,475–0,802, &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0,0001) et une antériorité plus faible de la consommation jours/semaines (OR : 0,251, IC&lt;sub&gt;95 %&lt;/sub&gt; : 0,125–0,506, &lt;em&gt;p&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0,0001) et mois/années (OR : 0,495, IC&lt;s","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"79 6","pages":"Pages 755-756"},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142698286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}